JP2009524670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009524670A5 JP2009524670A5 JP2008552395A JP2008552395A JP2009524670A5 JP 2009524670 A5 JP2009524670 A5 JP 2009524670A5 JP 2008552395 A JP2008552395 A JP 2008552395A JP 2008552395 A JP2008552395 A JP 2008552395A JP 2009524670 A5 JP2009524670 A5 JP 2009524670A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- saturated
- heteroaryl
- partially unsaturated
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920006395 saturated elastomer Polymers 0.000 claims 54
- 125000000217 alkyl group Chemical group 0.000 claims 46
- 125000000623 heterocyclic group Chemical group 0.000 claims 45
- 125000001072 heteroaryl group Chemical group 0.000 claims 38
- 125000003118 aryl group Chemical group 0.000 claims 30
- 125000003342 alkenyl group Chemical group 0.000 claims 28
- 125000000304 alkynyl group Chemical group 0.000 claims 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000004043 oxo group Chemical group O=* 0.000 claims 16
- 125000004404 heteroalkyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- -1 t- butyl Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 102000030595 Glucokinase Human genes 0.000 claims 4
- 108010021582 Glucokinase Proteins 0.000 claims 4
- 125000004450 alkenylene group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003054 catalyst Substances 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 claims 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 claims 1
- ZRHUHDUEXWHZMA-UHFFFAOYSA-N 1,4-dihydropyrazol-5-one Chemical compound O=C1CC=NN1 ZRHUHDUEXWHZMA-UHFFFAOYSA-N 0.000 claims 1
- LJKOFHPXVQFIQA-UHFFFAOYSA-N 1-[4-[2-[[4-(2,6-dichlorophenyl)sulfanylpyridin-2-yl]amino]-1,3-thiazol-4-yl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C1=CSC(NC=2N=CC=C(SC=3C(=CC=CC=3Cl)Cl)C=2)=N1 LJKOFHPXVQFIQA-UHFFFAOYSA-N 0.000 claims 1
- ZNEVZQJMMIYNCM-UHFFFAOYSA-N 1-[4-[2-[[4-(2,6-dimethylphenoxy)pyridin-2-yl]amino]-1,3-thiazol-4-yl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C1=CSC(NC=2N=CC=C(OC=3C(=CC=CC=3C)C)C=2)=N1 ZNEVZQJMMIYNCM-UHFFFAOYSA-N 0.000 claims 1
- UTIDUWCJLKFEMM-UHFFFAOYSA-N 1-[4-[2-[[4-(2-chloro-6-methylphenoxy)pyridin-2-yl]amino]-1,3-thiazol-4-yl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C1=CSC(NC=2N=CC=C(OC=3C(=CC=CC=3C)Cl)C=2)=N1 UTIDUWCJLKFEMM-UHFFFAOYSA-N 0.000 claims 1
- GBASZHHIBQYYME-UHFFFAOYSA-N 1-[4-[2-[[4-(2-chlorophenoxy)pyridin-2-yl]amino]-1,3-thiazol-4-yl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C1=CSC(NC=2N=CC=C(OC=3C(=CC=CC=3)Cl)C=2)=N1 GBASZHHIBQYYME-UHFFFAOYSA-N 0.000 claims 1
- GKGPSKQWWOBPCF-UHFFFAOYSA-N 3-[2-[[3-(1-acetylpiperidin-4-yl)-1,2,4-thiadiazol-5-yl]amino]-5-bromopyridin-4-yl]oxy-4-chloro-n-[2-(dimethylamino)ethyl]benzamide Chemical compound CN(C)CCNC(=O)C1=CC=C(Cl)C(OC=2C(=CN=C(NC=3SN=C(N=3)C3CCN(CC3)C(C)=O)C=2)Br)=C1 GKGPSKQWWOBPCF-UHFFFAOYSA-N 0.000 claims 1
- CJTXXGSSOGGONY-UHFFFAOYSA-N 3-[2-[[4-(1-acetylpiperidin-4-yl)-1,3-thiazol-2-yl]amino]pyridin-4-yl]oxypyridine-4-carbonitrile Chemical compound C1CN(C(=O)C)CCC1C1=CSC(NC=2N=CC=C(OC=3C(=CC=NC=3)C#N)C=2)=N1 CJTXXGSSOGGONY-UHFFFAOYSA-N 0.000 claims 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims 1
- 0 CC(C)c1nc(*)c(*)[s]1 Chemical compound CC(C)c1nc(*)c(*)[s]1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76317306P | 2006-01-27 | 2006-01-27 | |
| US60/763,173 | 2006-01-27 | ||
| PCT/US2007/001956 WO2007089512A1 (en) | 2006-01-27 | 2007-01-24 | Glucokinase activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009524670A JP2009524670A (ja) | 2009-07-02 |
| JP2009524670A5 true JP2009524670A5 (OSRAM) | 2011-02-24 |
| JP5236499B2 JP5236499B2 (ja) | 2013-07-17 |
Family
ID=38109991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552395A Expired - Fee Related JP5236499B2 (ja) | 2006-01-27 | 2007-01-24 | グルコキナーゼ活性化剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8022222B2 (OSRAM) |
| EP (1) | EP1986645B1 (OSRAM) |
| JP (1) | JP5236499B2 (OSRAM) |
| CN (1) | CN101437512A (OSRAM) |
| AT (1) | ATE539748T1 (OSRAM) |
| CA (1) | CA2637172A1 (OSRAM) |
| ES (1) | ES2378704T3 (OSRAM) |
| TW (1) | TW200740804A (OSRAM) |
| WO (1) | WO2007089512A1 (OSRAM) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008091770A1 (en) * | 2007-01-24 | 2008-07-31 | Array Biopharma Inc. | 2-aminopyridine derivatives as glucokinase activators |
| US8362037B2 (en) * | 2007-03-23 | 2013-01-29 | Array Biopharma, Inc. | 2-aminopyridine analogs as glucokinase activators |
| WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| WO2009022179A2 (en) * | 2007-08-14 | 2009-02-19 | Astrazeneca Ab | Glucokinase activators in the treatment of osteoarthritis |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP3078662A1 (en) | 2007-09-21 | 2016-10-12 | Array Biopharma, Inc. | Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
| AU2008310097B2 (en) | 2007-10-09 | 2013-05-16 | Merck Patent Gmbh | Pyridine derivatives useful as glucokinase activators |
| JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ４−ピリジノン化合物および癌についてのその使用 |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| WO2010058846A1 (ja) | 2008-11-21 | 2010-05-27 | アステラス製薬株式会社 | ４，６-ジアミノニコチンアミド化合物 |
| AU2009326148B2 (en) | 2008-12-11 | 2014-05-08 | Respivert Limited | p38 MAP kinase inhibitors |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| AU2011235212B2 (en) | 2010-03-31 | 2014-07-31 | The Scripps Research Institute | Reprogramming cells |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| JP5787977B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤 |
| EP2556067B1 (en) | 2010-04-08 | 2016-02-24 | Respivert Limited | Pyrazolyl ureas as p38 map kinase inhibitors |
| US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| KR20180099933A (ko) * | 2010-11-19 | 2018-09-05 | 리간드 파마슈티칼스 인코포레이티드 | 복소환 아민 및 이의 용도 |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012121314A1 (ja) | 2011-03-09 | 2012-09-13 | 第一三共株式会社 | ジピリジルアミン誘導体 |
| CN102786517B (zh) * | 2011-05-18 | 2017-06-06 | 中国医学科学院药物研究所 | Gk和ppar双重激动活性的嘧啶噻唑胺类衍生物 |
| JP5748210B2 (ja) * | 2011-05-26 | 2015-07-15 | 日本化薬株式会社 | 複素環化合物の製造方法 |
| SG10201604682VA (en) * | 2011-06-10 | 2016-07-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| US9133174B2 (en) | 2011-09-05 | 2015-09-15 | Chugai Seiyaku Kabushiki Kaisha | Method for producing coumarin derivative |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| TW201329067A (zh) * | 2011-12-08 | 2013-07-16 | Amgen Inc | 作為ｇｋａ活化劑之脲化合物 |
| WO2013173672A1 (en) | 2012-05-18 | 2013-11-21 | Array Biopharma Inc. | Method for the preparation of thiadiazoles |
| WO2014074657A1 (en) * | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| WO2014159938A1 (en) * | 2013-03-13 | 2014-10-02 | The Broad Institute, Inc. | Substituted aminothiazoles for the treatment of tuberculosis |
| WO2016001341A1 (en) * | 2014-07-03 | 2016-01-07 | F. Hoffmann-La Roche Ag | Sulfonylaminopyridine compounds, compositions and methods of use |
| CN106749002A (zh) * | 2015-02-12 | 2017-05-31 | 佛山市赛维斯医药科技有限公司 | 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途 |
| JP6483272B2 (ja) * | 2015-02-17 | 2019-03-13 | グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ | 白色脂肪組織の褐色化を誘導するための化合物および方法 |
| US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
| JP2018515597A (ja) * | 2015-04-07 | 2018-06-14 | イーエルエイ ファーマ リミテッドＥｌａ Ｐｈａｒｍａ Ｌｔｄ | カテプシンｃおよび／またはｃｅｌａ１および／またはｃｅｌａ３ａおよび／またはそれらに構造的に関連する酵素を特異的に標的とする細胞および／または組織壊死の処置および／または防止のための組成物 |
| US10759739B2 (en) * | 2015-06-11 | 2020-09-01 | University of Pittsburgh—of the Commonwealth System of Higher Education | P62-ZZ small molecule modulators |
| US10894784B2 (en) | 2015-12-18 | 2021-01-19 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| CN109952303B (zh) * | 2016-10-14 | 2022-10-21 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| EP3990445A4 (en) * | 2019-06-25 | 2023-07-05 | InventisBio Co., Ltd. | HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARATION AND THEIR METHODS OF USE |
| CN110898049B (zh) * | 2019-11-29 | 2021-09-14 | 华中师范大学 | 二硫化合物在制备药物中的应用、fbp酶抑制剂及用于预防和/或治疗糖尿病的药剂 |
| US11753403B2 (en) | 2020-03-03 | 2023-09-12 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| WO2022147694A1 (en) * | 2021-01-06 | 2022-07-14 | Beijing Erai Therapeutics Co., Ltd. | Aminoheteroaryl compounds and uses thereof |
| CA3229560A1 (en) | 2021-08-25 | 2023-03-02 | Christopher L. Vandeusen | Eif4e inhibitors and uses thereof |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2384101A1 (en) * | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1404672B1 (en) * | 2001-06-22 | 2006-01-18 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| DE60314603T2 (de) | 2002-03-15 | 2008-02-28 | Vertex Pharmaceuticals Inc., Cambridge | Zusammensetzungen brauchbar als protein-kinase-inhibitoren |
| US20040023978A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Active salt forms with tyrosine kinase activity |
| US20040023981A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Salt forms with tyrosine kinase activity |
| JP2006509774A (ja) * | 2002-10-03 | 2006-03-23 | ノバルティス アクチエンゲゼルシャフト | ２型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換（チアゾール−２−イル）−アミドまたはスルホンアミド |
| WO2004041164A2 (en) * | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Kinase inhibitors |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| GB0328178D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| AU2005264213A1 (en) * | 2004-05-21 | 2006-01-26 | Msd K.K. | Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton |
| NZ556433A (en) * | 2005-01-14 | 2010-10-29 | Cgi Pharmaceuticals Inc | 1, 3-diaryl substituted ureas as modulators of kinase activity |
| US20090105250A1 (en) * | 2005-01-26 | 2009-04-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP2008543754A (ja) * | 2005-06-09 | 2008-12-04 | メルク エンド カムパニー インコーポレーテッド | チェックポイントキナーゼの阻害剤 |
-
2007
- 2007-01-24 JP JP2008552395A patent/JP5236499B2/ja not_active Expired - Fee Related
- 2007-01-24 US US12/161,366 patent/US8022222B2/en not_active Expired - Fee Related
- 2007-01-24 WO PCT/US2007/001956 patent/WO2007089512A1/en not_active Ceased
- 2007-01-24 CA CA002637172A patent/CA2637172A1/en not_active Abandoned
- 2007-01-24 CN CNA2007800107261A patent/CN101437512A/zh active Pending
- 2007-01-24 EP EP07716991A patent/EP1986645B1/en not_active Not-in-force
- 2007-01-24 AT AT07716991T patent/ATE539748T1/de active
- 2007-01-24 ES ES07716991T patent/ES2378704T3/es active Active
- 2007-01-25 TW TW096102803A patent/TW200740804A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009524670A5 (OSRAM) | ||
| AU2019283921B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| CN105764514B (zh) | 作为tam族激酶抑制剂的氨基吡啶衍生物 | |
| JP2014506599A5 (OSRAM) | ||
| AU2015236428B2 (en) | TrkA kinase inhibitors, compositions and methods thereof | |
| JP2012528166A5 (OSRAM) | ||
| JP2017501234A5 (OSRAM) | ||
| TW200815427A (en) | Organic compounds | |
| JP7148660B2 (ja) | ３－（（ヘテロ－）アリール）－８－アミノ－２－オキソ－１，３－ジアザ－スピロ－［４．５］－デカン誘導体 | |
| JP2015531772A (ja) | 融合二環式スルファモイル誘導体並びにｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2011507849A5 (OSRAM) | ||
| JP2009530410A5 (OSRAM) | ||
| JP2017512794A5 (OSRAM) | ||
| JP7627008B2 (ja) | ピロール化合物 | |
| JP2017508766A5 (OSRAM) | ||
| CN102869661A (zh) | 抗感染化合物 | |
| JP2007510689A5 (OSRAM) | ||
| JP2015508402A (ja) | ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用 | |
| JP2017512786A5 (OSRAM) | ||
| AU2017237930A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| JP2025515484A (ja) | Ｋｉｆ１８ａを阻害するための化合物 | |
| JP2022534501A (ja) | 三環式化合物 | |
| JP2020520925A5 (OSRAM) | ||
| US12344600B2 (en) | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | |
| JPWO2021020585A5 (OSRAM) |